Antibody that binds zinc transporter protein 108P5H8
View Patent ↗A novel gene (designated 108P5H8) and its encoded protein, and variants thereof, are described wherein 108P5H8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 108P5H8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 108P5H8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P1E1B can be used in active or passive immunization.
1. An isolated monoclonal antibody or antibody fragment that specifically binds to a protein having an amino acid sequence of SEQ ID NO: 2570.
2. The antibody or antibody fragment of claim 1 , wherein the monoclonal antibody is recombinantly produced.
3. The antibody or antibody fragment of claim 1 , wherein the antibody or fragment is labeled with a detectable marker.
4. The antibody or antibody fragment of claim 1 , wherein the fragment is selected from the group consisting of Fab, F(ab′)2, Fv and sFv.
5. The antibody or antibody fragment of claim 1 , wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.
6. A hybridoma that produces monoclonal antibody that specifically binds to a protein having an amino acid sequence of SEQ ID NO: 2570.
7. The antibody or antibody fragment of claim 2 , wherein the monoclonal antibody is a single chain monoclonal antibody.
8. The antibody or antibody fragment of claim 1 , wherein the antibody or fragment is labeled with an agent.
9. The antibody or antibody fragment of claim 8 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins.
10. The antibody or antibody fragment of claim 9 , wherein the radioactive isotope is selected from the group consisting of 211 At, 131 I, 125 I, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P and radioactive isotopes of Lu.
11. The antibody or antibody fragment of claim 9 , wherein the chemotherapeutic agent is selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin.
12. The antibody or antibody fragment of claim 9 , wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.